|Bid||20.01 x 1200|
|Ask||20.08 x 27000|
|Day's Range||19.96 - 20.08|
|52 Week Range||2.23 - 20.45|
|Beta (5Y Monthly)||2.20|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 5, 2020 - Mar 9, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||17.00|
WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of ArQule, Inc. ("ArQule" or the "Company") (NASDAQ: ARQL) in connection with the proposed acquisition of the Company by a subsidiary of Merck & Co., Inc. (NYSE: MRK). Under the terms of the acquisition agreement, ARQL shareholders will receive $20 per share in cash. The deal is scheduled to close in the first quarter of 2020.
WILMINGTON, Del., Dec. 12, 2019 -- Rigrodsky & Long, P.A. announces that it is investigating: Progenics Pharmaceuticals, Inc. (NASDAQ GS: PGNX) regarding possible.
A handful of sickle cell disease treatments and CAR-T therapies that treat cancer have been approved by the Food and Drug Administration in recent years, but a new crop of investigational therapies that would grow those markets is exciting investors.
Principia Biopharma stock has rocketed 32% this week amid enthusiasm for its technology, BTK inhibition — highlighted by notable moves from pharmaceutical giants Merck and Sanofi.
NEW YORK, NY / ACCESSWIRE / December 11, 2019 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Dec. 10) Acceleron Pharma Inc (NASDAQ: XLRN ) Aimmune Therapeutics ...
BALA CYNWYD, PA / ACCESSWIRE / December 10, 2019 / Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of ArQule, Inc. ("ArQule" ...
Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating ArQule, Inc ("ArQule" or the "Company") (Nasdaq: ARQL) relating to the sale of the Company to Merck Sharp & Dohme Corp. Under the terms of the Merger, ArQule shareholders will have the right to receive $20.00 in cash for each share of ArQule common stock owned.
Merck (MRK) offers to acquire ArQule for a deal value of $2.7 billion. The transaction will add ArQule's lead investigational candidate ARQ 531 to Merck's oncology portfolio.
The following are top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Dec. 9.) Acceleron Pharma Inc (NASDAQ: XLRN ) Aimmune Therapeutics ...
A string of multibillion-dollar pharmaceutical deals announced over the last week call attention to a record-setting year in which drugmakers and biotechs have spent $342 billion snapping up smaller companies to bolster their pipelines.
Dow book a triple-digit loss Monday, and all three major U.S. stock indexes end lower, as investors wait on global central bank policy updates this week and a key tariff deadline on Sunday.
ArQule stock rocketed more than 100% on Monday after Dow Jones stock Merck pledged to buy it for $2.7 billion. The biotech company is working on precision medicine in cancer treatment.
U.S. stocks pulled back on Monday from near-record levels, as Apple and healthcare shares fell and investors braced for a busy week of political and economic news, including a potential turning point in the U.S.-China trade dispute. Investor hopes of at least an initial U.S.-China agreement have helped push major stock indexes to record highs, with the benchmark S&P 500 hovering about 0.5% below its all-time high. "The market is ... in a little bit of a wait-and-see mode," said Chuck Carlson, chief executive officer at Horizon Investment Services in Hammond, Indiana.
"There is optimism about the potential of a roll back or some positive news on trade that is keeping stocks where they are," said Randy Frederick, vice president of trading and derivatives for Charles Schwab in Austin, Texas. The S&P 500 came within striking distance of a record high hit two weeks ago.
NEW YORK, NY / ACCESSWIRE / December 9, 2019 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased ArQule, Inc. ("ArQule" or the "Company") ...
Continuing with last's week trend of consolidation in the industry, two major players Merck (NYSE: MRK) and Sanofi (NYSE: SNY), made acquisitions to bolster their pipeline and augment future growth. One was telegraphed by the price action at the end of last week and the other was kept under wraps. The price action last week in Arqule Inc (NASDAQ: ARQL) gave no indication that the company was going to be taken out for $20/share as it posted a modest 9-cent gain for the week.
Bragar Eagel & Squire, P.C., a nationally recognized stockholder law firm, has launched an investigation into whether the board members of ArQule, Inc. (NASDAQ: ARQL) breached their fiduciary duties or violated the federal securities laws in connection with the company's proposed sale to Merck & Co.
WILMINGTON, DE / ACCESSWIRE / December 9, 2019 / Rigrodsky & Long, P.A.: Do you own shares of ArQule, Inc. (NASDAQ GM: ARQL )? Did you purchase any of your shares prior to December 9, 2019? Do you think ...
Benzinga Pro's Stocks To Watch For Monday Merck (MRK) - Reported it will purchase ArQule (ARQL) in a deal valued at $2.7 billion. The purchase price for ArQule was $20/share in cash. ArQule shares were ...
NEW YORK, Dec. 09, 2019 -- Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of ArQule, Inc. (NASDAQ: ARQL) to Merck for $20.00 per share.